[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 8570 Introduced in House (IH)]
<DOC>
118th CONGRESS
2d Session
H. R. 8570
To establish a pharmacy program to award grants for safe in-home drug
disposal and practical medication safety education, and for other
purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 24, 2024
Mr. Hudson introduced the following bill; which was referred to the
Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To establish a pharmacy program to award grants for safe in-home drug
disposal and practical medication safety education, and for other
purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Safe In-Home Drug Disposal
Initiative Act of 2024'' or the ``SIDDI Act of 2024''.
SEC. 2. SAFE IN-HOME DRUG DISPOSAL INITIATIVE.
(a) In General.--Not later than 180 days after the date of
enactment of this Act, the Secretary of Health and Human Services,
acting through the Assistant Secretary for Mental Health and Substance
Use, (in this section referred to as the ``Secretary'') shall establish
a program to award grants to States to implement targeted State
demonstration initiatives (in this section referred to as ``TSDIs'').
Such TSDIs shall reimburse licensed pharmacies that choose to
participate in the TSDI (in this section referred to as ``participating
pharmacies'') for the provision to eligible patients, in coordination
with the delivery of drug prescriptions, of in-home drug disposal
systems and standard medication safety education.
(b) Application.--To be eligible to receive a grant under this
section, a State shall submit to the Secretary an application at such
time, in such manner, and containing such information as the Secretary
may require. Such an application shall--
(1) identify the State agency that oversees pharmaceutical
care and will be responsible for administering a TSDI through a
grant under this section;
(2) identify the single pharmacy benefit manager (commonly
known as a ``PBM'') that will be responsible for--
(A) adjudicating claims under the TSDI;
(B) reimbursing participating pharmacies; and
(C) facilitating the type of customization required
to successfully administer a custom, fully transparent
program, with pass-through claims adjudication services
benefitting patients, plans, and pharmacies;
(3) outline the process by which participating pharmacies
will submit usual and customary costs related to the
reimbursement and remuneration of services, including detailed
reporting on--
(A) criteria of patient selection;
(B) initial activity; and
(C) patient engagement factors;
(4) detail the process through which standard medication
safety education will be communicated by each participating
pharmacist or pharmacy technician at the point of dispensing,
allowing for unique needs and education to be tailored for
State-, county-, town-, and municipality-specific needs;
(5) detail a plan to increase participation rates of
pharmacists and pharmacy technicians through a single
electronic pharmacy claim process;
(6) state the remuneration amounts for the provision of
standard medication safety education, and the reimbursement
amounts for in-home drug disposal systems, which for each
eligible patient shall be assessed separately but processed
through a single electronic claim;
(7) describe how the State will select pharmacies to be
served under the TSDI; and
(8) include the number of eligible patients to be served
under the TSDI.
(c) Number.--The Secretary shall award grants under this section to
not more than 5 States.
(d) Grant Period.--A grant awarded under this section shall be for
a period of at least 3 years.
(e) Accountability and Oversight.--As a condition of receiving a
grant under this section, a State shall agree to submit to the
Secretary, at such time and in such manner as the Secretary may
reasonably require, a report on the TSDI of the State implemented
through such grant. Such report shall--
(1) list the number of pharmacy locations that are
reimbursed through the grant funds;
(2) describe the activities undertaken by the State using
the grant amounts, outlining the in-home drug disposal
solutions distributed and the patient education delivered;
(3) survey pharmacies to collect demographic information on
participating patients, medication types prescribed, and the
effective use of the in-home drug disposal systems; and
(4) contain performance measures relating to the
effectiveness of the grant, including changes in the
participation rate of eligible patients and the engagement with
pharmacists.
(f) Definitions.-- In this section:
(1) Eligible patients.--The term ``eligible patients''
means patients receiving an opioid prescription who are at risk
of experiencing an opioid-related overdose, including such
patients--
(A) with a first-time opioid prescription;
(B) with an acute opioid prescription prescribed
for a short-term illness or condition; or
(C) that have received a change in the opioid
dosage of an acute or chronic opioid prescription.
(2) In-home drug disposal system.-- The term ``in-home drug
disposal system'' means a system of drug disposal--
(A) that changes the physical integrity of the
formulation of a drug;
(B) that renders the active ingredients of such
drug unusable for all practical purposes;
(C) that--
(i) is nontoxic and nonhazardous;
(ii) poses no threat to the consumer; and
(iii) reduces drug exposure to the
environment; and
(D) that acts as a deterrent for misuse of drugs.
(3) Standard medication safety education.--The term
``standard medication safety education'' means medication
safety education--
(A) provided by a pharmacist or pharmacy technician
to eligible patients for a duration of not more than 5
minutes per patient; and
(B) that includes information relating to--
(i) proper medication storage;
(ii) risks associated with keeping unused
medication in the home;
(iii) proper in-home disposal of unused
medication; and
(iv) in the case of naloxone that is
prescribed as an opioid medication, the proper
use of such naloxone
(4) State.--The term ``State'' means each of the several
States, the District of Columbia, and any territory of the
United States.
(g) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section $56,000,000 for the period of
fiscal years 2025 through 2029.
<all>